Company Overview
4D Molecular Therapeutics, Inc. is a late-stage biotechnology entity focused on the development of adeno-associated virus vectors derived from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution, which operates facilities in both the Netherlands and the United States. The company functions within the healthcare sector, specifically inside the biotechnology industry, positioning it to potentially deliver novel therapies that address significant medical needs through advanced vector technology. Its current scale is defined by a market capitalization of $504.39M, annual revenue of $85.21M, and a workforce comprising 196 employees. These financial figures indicate that the company holds a substantial market presence relative to its revenue stream, suggesting significant operational leverage or a valuation that heavily weights future potential rather than current profitability. The disparity between its relatively modest revenue and its market cap highlights that the market is pricing the stock based on its late-stage development pipeline rather than established cash flows, which is a common characteristic for biotechnology firms in the sector.
Financial Health
The company reported revenue of $85.21M for the trailing twelve months, yet it recorded a net income of $-140,108,992 and an EBITDA of $-151,652,992, revealing a cost structure where expenses significantly outpace income generation. This substantial gap between revenue and net income indicates that the company is currently burning cash to fund research and development activities typical of a late-stage biotechnology firm. Free cash flow stands at $-54,154,876, which reflects a capital-intensive operational model where the company must continuously invest in clinical trials and vector manufacturing to advance its product candidates. Despite the negative cash flow, the balance sheet supports operations with $402.66M in cash against $21.41M in debt, creating a liquidity buffer that exceeds total liabilities by a wide margin. The debt-to-equity ratio is recorded at 4.24, which suggests a leveraged capital structure, though the high cash reserves mitigate the immediate risk associated with this leverage. Operating margin figures show an operating margin of 17.4%, while gross margin is reported at -125.9% and profit margin at -164.4%, indicating that standard cost accounting methods may be capturing significant non-recurring or development-related costs in the gross line item. Return on Equity is -27.6% and Return on Assets is -17.3%, metrics that mathematically reveal that management is currently deploying capital to generate losses rather than profits, a standard phase for development-stage companies. The current ratio is 9.39, an extremely high figure that indicates robust short-term liquidity and an overwhelming ability to cover short-term obligations with available current assets.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the lack of earnings, while the forward P/E is -2.63, a metric that implies the market expects earnings to remain negative or for the company to continue operating at a loss in the near term. The price-to-book ratio is 1.13, suggesting that the market values the company slightly above its book value, potentially reflecting confidence in the intangible value of its proprietary vector platform. The price-to-sales ratio is 5.92, and the EV/EBITDA is -0.81, both of which serve as alternative valuation metrics that price the stock based on revenue multiple rather than earnings, a common practice for unprofitable biotechnology assets. The stock has a 52-week high of $12.34 and a 52-week low of $2.23, placing the current valuation context within a wide historical trading range that reflects high investor sentiment volatility. The beta value is 3.01, which indicates that the stock price is expected to be significantly more volatile than the broader market, moving with greater intensity during periods of market stress or gain.
Growth & Income
Revenue growth year-over-year is listed as 8508900.0%, a figure that often reflects a change in accounting methodology or a one-time event rather than organic expansion, while earnings growth is N/A due to the lack of positive earnings to measure against prior periods. Because the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company reinvests all available resources into its research and development pipeline rather than distributing cash to shareholders. The overall growth and income profile is characterized by high revenue volatility and a complete absence of dividend income, typical for a late-stage biotechnology company focused on capitalizing on future product approvals.